Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
6.53
-0.11 (-1.66%)
Nov 5, 2024, 1:24 PM EST - Market open

Company Description

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.

The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.

Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals logo
Country United States
Founded 2013
IPO Date Apr 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 500
CEO Christopher Gibson

Contact Details

Address:
41 South Rio Grande Street
Salt Lake City, Utah 84101
United States
Phone 385 269 0203
Website recursion.com

Stock Details

Ticker Symbol RXRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001601830
CUSIP Number 75629V104
ISIN Number US75629V1044
Employer ID 46-4099738
SIC Code 2836

Key Executives

Name Position
Dr. Christopher C. Gibson Ph.D. Co-Founder, Chief Executive Officer and Director
Tina Marriott Larson Chief Operating Officer and President
Dr. Blake C. Borgeson Ph.D. Co-Founder and Director
Dr. Michael Secora Ph.D. Chief Financial Officer
Dr. David J. Mauro M.D., Ph.D. Chief Medical Officer
Kevin Leggat Vice President of Finance and Accounting
Benjamin Mabey M.S. Chief Technology Officer
Jared Allenbach Senior Director of Investor Relations
Nathan Hatfield Chief Legal Officer and General Counsel
Ryan Kelly Chief Communications Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 SCHEDULE 13G/A Filing
Oct 30, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 29, 2024 144 Filing
Oct 24, 2024 144 Filing
Oct 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 17, 2024 144 Filing
Oct 15, 2024 144 Filing